Article
Kissimmee, Fla. — The time it takes for the U.S. Food and Drug Administration (FDA) approval of a new dermatology drug or treatment depends on many factors, including how closely pharmaceutical companies cooperate with the agency.
Review Compares Psoriasis Therapies in Asian Populations
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Patients Treated for Acne Exhibit Higher Sebum, Hydration, and TEWL Levels than General Population
Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases